Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Constellation Energy Corporation (CEG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Constellation Energy Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Constellation Energy Corporation trades at $250.25 (market cap $89.77B). The key difference: Constellation Energy Corporation is far larger — about 2.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Constellation Energy Corporation pays a 0.68% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CEG | |
|---|---|---|
Market Cap | $39.89B | $89.77B |
Sector | Health | Energy |
52-Week High | $491.22 | $403.95 |
52-Week Low | $278.09 | $236.50 |
Enterprise Value | $38.15B | $111.43B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Constellation Energy (CEG) trades at $251.38, up 0.26% with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with 12.69% net margin and 16.33% ROE, supported by positive earnings beats in recent quarters. Analyst consensus remains strongly bullish with a $343.50 price target, representing 37% upside potential. Recent news highlights CEG's strategic positioning to benefit from AI-driven electricity demand and nuclear power resurgence.
CEG offers compelling growth exposure to clean energy transition with nuclear power advantages, though technical weakness and significant capital expenditures pose near-term challenges. The company's long-term power purchase agreements with major corporations provide revenue visibility, while valuation multiples remain reasonable relative to growth prospects. Execution on capital projects and regulatory developments represent key monitoring points for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →
